DK0939632T3 - Non-peptidyl vasopressin V1a antagonister - Google Patents

Non-peptidyl vasopressin V1a antagonister

Info

Publication number
DK0939632T3
DK0939632T3 DK97907895T DK97907895T DK0939632T3 DK 0939632 T3 DK0939632 T3 DK 0939632T3 DK 97907895 T DK97907895 T DK 97907895T DK 97907895 T DK97907895 T DK 97907895T DK 0939632 T3 DK0939632 T3 DK 0939632T3
Authority
DK
Denmark
Prior art keywords
antagonists
vasopressin
peptidyl
peptidyl vasopressin
azetidin
Prior art date
Application number
DK97907895T
Other languages
Danish (da)
English (en)
Inventor
Robert F Bruns Jr
Gary A Koppel
Robin D G Cooper
Bruce A Dressman
David C Hunden
Stephen W Kaldor
John R Rizzo
Jeffrey James Skelton
Mitchell I Steinberg
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605046.3A external-priority patent/GB9605046D0/en
Priority claimed from GBGB9605045.5A external-priority patent/GB9605045D0/en
Priority claimed from GBGB9605044.8A external-priority patent/GB9605044D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0939632T3 publication Critical patent/DK0939632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DK97907895T 1996-02-23 1997-02-20 Non-peptidyl vasopressin V1a antagonister DK0939632T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1221596P 1996-02-23 1996-02-23
US1214996P 1996-02-23 1996-02-23
US1218896P 1996-02-23 1996-02-23
GBGB9605046.3A GB9605046D0 (en) 1996-03-09 1996-03-09 Method for antagonism of the tachykinin receptor with non-peptide agents
GBGB9605045.5A GB9605045D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the oxytocin receptor
GBGB9605044.8A GB9605044D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the vasopressin v1a receptor

Publications (1)

Publication Number Publication Date
DK0939632T3 true DK0939632T3 (da) 2006-01-30

Family

ID=27547258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907895T DK0939632T3 (da) 1996-02-23 1997-02-20 Non-peptidyl vasopressin V1a antagonister

Country Status (10)

Country Link
US (3) US6204260B1 (enExample)
EP (1) EP0939632B1 (enExample)
JP (1) JP4212112B2 (enExample)
AT (1) ATE305781T1 (enExample)
AU (1) AU1977997A (enExample)
CA (1) CA2246753C (enExample)
DE (1) DE69734321T2 (enExample)
DK (1) DK0939632T3 (enExample)
ES (1) ES2248840T3 (enExample)
WO (1) WO1997030707A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
WO2001012171A2 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
SK6052002A3 (en) 1999-11-04 2003-09-11 Ortho Mcneil Pharm Inc Nonpeptide substituted benzothiazepines as vasopressin antagonists
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
DK1406893T3 (da) 2001-06-15 2007-08-06 Vicuron Pharm Inc Bicykliske pyrrolidinforbindelser
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
WO2003051314A2 (en) * 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
MXPA05003477A (es) * 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
WO2005035492A1 (en) * 2003-10-03 2005-04-21 Serenix Pharmaceuticals, Llc. 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006133411A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
JP2012525427A (ja) * 2009-04-29 2012-10-22 レクサン ファーマシューティカルズ インコーポレイテッド 神経保護および神経変性疾患の治療のためのクラブラン酸塩製剤
AU2011272738B2 (en) * 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US4673737A (en) 1985-08-02 1987-06-16 Harvard University 7-acylamino-(or 7-amino)-3-trifluoromethylsulfonyloxy-1-carba(1-dethia)-3-cephem-4-carboxylic acids and esters thereof
ES2000907A6 (es) 1985-09-09 1988-03-16 Otsuka Pharma Co Ltd Procedimiento de preparar compuestos 2-oxaisocefen microbiologicamente activos
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
KR960002856B1 (ko) 1987-03-09 1996-02-27 오쓰까 세이야꾸 가부시끼가이샤 2-옥사-이소세펨 화합물, 이를 함유하는 조성물 및 이의 제조방법
US5373089A (en) 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
US5068232A (en) * 1990-04-10 1991-11-26 American Cyanamid Company Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
US5521307A (en) 1992-02-18 1996-05-28 Eli Lilly And Company Methods and compounds for the preparation of carbacephems
CA2147129A1 (en) * 1992-10-27 1994-05-11 James B. Doherty New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996016333A1 (en) * 1994-11-23 1996-05-30 Affymax Technologies, N.V. METHODS FOR SYNTHESIZING DIVERSE COLLECTIONS OF β-LACTAM COMPOUNDS
ATE197591T1 (de) * 1995-03-31 2000-12-15 Naeja Pharmaceutical Inc 4-substituierte-3-peptidyl-azetidin-2-on-deriva e als cystein-proteinase inhibitoren
WO1996035122A1 (en) * 1995-05-03 1996-11-07 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs

Also Published As

Publication number Publication date
JP4212112B2 (ja) 2009-01-21
US6521611B2 (en) 2003-02-18
US20020049187A1 (en) 2002-04-25
EP0939632B1 (en) 2005-10-05
EP0939632A1 (en) 1999-09-08
JP2000504731A (ja) 2000-04-18
EP0939632A4 (en) 2002-09-25
WO1997030707A1 (en) 1997-08-28
US6204260B1 (en) 2001-03-20
CA2246753C (en) 2005-05-10
ES2248840T3 (es) 2006-03-16
ATE305781T1 (de) 2005-10-15
AU1977997A (en) 1997-09-10
DE69734321T2 (de) 2006-08-10
CA2246753A1 (en) 1997-08-28
DE69734321D1 (de) 2006-02-16
US6610680B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
DE69734321D1 (de) Non-peptidische vasopressin via antagonisten
PT776324E (pt) Antagonista da endotelina
ATE263151T1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
AU3998693A (en) Angiotensin ii antagonists
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
AU2464601A (en) Tricyclic protein kinase inhibitors
EA199700061A1 (ru) Способ получения силденафила
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
MA24632A1 (fr) Derives de 2-(4-aryl-ou heteroaryl-piperazine-1-ylmethyle)-1h- indole
DE69717449D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ATE208764T1 (de) Isazole derivate als fibrinogen-rezeptor- antagonisten
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии
ATE342055T1 (de) Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle
HK1008990A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
FI941117L (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
HK1025569A (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
BR0002142A (pt) Inibidores de quinase myti